PushButton AI Team ·
You bought the AI tool. Nobody used it. $200/month quietly disappearing. That's not a you problem. That's a rollout problem. Here's what's interesting about what's happening in pharma right now. B
You bought the AI tool. Nobody used it. $200/month quietly disappearing.
That's not a you problem. That's a rollout problem.
Here's what's interesting about what's happening in pharma right now.
Bristol Myers Squibb just struck a major AI integration agreement — not to replace their people or rebuild their systems. To plug AI into specific supply chain decisions that were already costing them money.
That's the pattern worth copying.
The companies actually winning with AI aren't starting over. They're finding one painful, repeatable process — forecasting, inventory, compliance tracking — and letting AI handle that one thing.
One problem. One tool. One measurable result.
The insight that transfers to your business: don't ask "what can AI do for us?" Ask "what's the one decision we make every week that costs us time and guesswork?"
That's your starting point. No coding. No overhaul. No six-month project.
Map that one decision to one tool, and you'll have your ROI story within 30 days.
What's the one repetitive decision in your business you'd most want off your plate right now?
Drop it below — I'll tell you if there's a straightforward AI fix for it.
#AIStrategy #BusinessGrowth #OperationalEfficiency #SmallBusiness
BMS-Claude Agreement Signals AI Integration Shift in Pharma. ByStephen Appezzato. May 21st 2026. Q&A: How RWE Is Reshaping Specialty Pharma Market ...